Evidence map›Paper›PMID 36402243›Full record

ReviewPharmacology, biochemistry, and behavior2022

Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.

Shalini Dogra, Jason Putnam, P Jeffrey Conn

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacology, biochemistry, and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shalini DograDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Jason PutnamDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: jeff.conn@vanderbilt.edu.
Vanderbilt University · US

Funding

REGULATION OF SIGNALING BY MGLUR5R01MH062646 · NIMH · VANDERBILT UNIVERSITY · PI P Jeffrey Conn, COLLEEN M NISWENDER · 2001 to 2026
$10.9M
FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPESR01NS031373 · NINDS · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 1993 to 2025
$6.2M
Discovery of mGlu receptor PAMs for treatment of schizophreniaR01MH119673 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2019 to 2023
$3.6M
Functional effects of mGluR potentiators in the CNSR01MH074953 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2006 to 2010
$1.4M
NIMH NIH HHS R01 MH062646NIMH NIH HHS R01 MH074953NIMH NIH HHS R01 MH119673NINDS NIH HHS R01 NS031373
6 · The paper itself

Abstract

Glutamate is a major excitatory neurotransmitter in the central nervous system (CNS) and abnormalities in the glutamatergic system underlie various CNS disorders. As metabotropic glutamate receptor 3 (mGlu

Indexed as

Nervous System DiseasesReceptors, Metabotropic GlutamateCentral Nervous SystemGlutamic AcidHumansGlutamic Acidmetabotropic glutamate receptor 3Receptors, Metabotropic GlutamateAntidepressantsCognitionDepressionGlutamatemGlu3mGlu5Neurodevelopmental disordersSchizophreniaSubstance use disorders

Identifiers

PMID36402243
PMCPMC9729465
OpenAlexW4309436811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.